WeissComm acquires ODA, expands offerings

Share this article:
WeissComm has announced the acquisition of ODA, a San Francisco-based creative shop focused on healthcare brands.

The move will allow WeissComm, a predominantly PR firm, to establish a creative department and expand its offerings. “Clients want integrated marketing programs,” said Jim Weiss, CEO. “Communication is not any one single discipline, it's much more broad,” he said, noting that WeissComm will work with ODA on a mutual basis.
In addition to the acquisition of ODA, WeissComm partnered with Seattle-based Health Advocacy Strategies (HAS), a patient testimonial company. HAS identifies and captures motivated patients, for use as a repository for brand spokespeople, explained Weiss. 

ODA's services include advertising, promotional materials, print collateral and a full-service interactive, web development capability, among other services. The agency scored work from Medtronic in December, to promote the company's portfolio of coronary vascular products.

Seattle-based HAS was founded by Robin Shapiro, a healthcare and biopharmaceutical veteran.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?